MethylGene Inc.
TSX : MYG

MethylGene Inc.

August 03, 2005 07:00 ET

MethylGene Second Quarter Conference Notice

MONTREAL, QUEBEC--(CCNMatthews - Aug. 3, 2005) - MethylGene Inc. (TSX:MYG) will release its second quarter results for the quarter ending June 30, 2005 prior to market open on August 11, 2005 and will host a conference call to discuss these results on the same day at 4:30 pm EST. MethylGene would like to invite all interested parties to participate by dialing 416-695-5261 or 1-877-461-2814. You will be put on hold until the conference call begins.

On the call from MethylGene will be:



Donald F. Corcoran President and CEO
Dr. Jeffrey M. Besterman Executive Vice-President, R&D and CSO
Klaus Kepper Vice-President Finance and CFO
Dr. Robert Martell Vice-President and CMO
Dr. Andrea Gilpin Director, Investor Relations & Project
Management


A question and answer session will follow, at which time the operator will direct participants as to the correct procedure for submitting questions.

A live audio webcast of the conference call will be available at www.methylgene.com.

A telephone replay of the conference call will also be available on August 11th, 2005 through August 25th, 2005. To access the replay, dial 416-695-6230 or 1-877-605-9320 and enter reservation number 6683.

About MethylGene

MethylGene is a publicly-traded biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics in cancer and infectious diseases. Two cancer product candidates are currently in clinical trials: MG98, partnered with MGI Pharma for North America and MGCD0103, partnered with Taiho Pharmaceutical for certain Asian countries.

MG98 has entered a randomized two-step Phase II combination trial with interferon alpha in metastatic renal cell cancer. MGCD0103 is currently in Phase I dose-escalation monotherapy trials against solid tumours and hematological malignancies. In collaboration with Merck, MethylGene is developing small molecule beta-lactamase inhibitors to overcome antibiotic resistance. MethylGene has a portfolio of preclinical programs for its multitargeted kinase and histone deacetylase (HDAC) inhibitors for both oncology and non-oncology indications, and is exploiting its core HDAC expertise for the treatment of neurodegenerative diseases with EnVivo Pharmaceuticals. Please visit MethylGene's website at www.methylgene.com.

Except for historical information, this press release may contain forward-looking statements, which reflect the Company's current expectation regarding future events. These forward-looking statements involve risk and uncertainties,(which can be found in the Company's Annual Information Form dated December 31, 2004 and can be found on www.sedar.com) which may cause but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time to time in the Company's ongoing quarterly and annual reporting.

Contact Information

  • MethylGene Inc.
    Donald F. Corcoran
    President & CEO
    (514) 337-3333 ext. 224
    (514) 337-0550 (FAX)
    corcorand@methylgene.com
    or
    MethylGene Inc.
    Andrea Gilpin
    Director, Investor Relations & Project Management
    (514) 337-3333 ext. 416
    (514) 337-0550 (FAX)
    gilpina@methylgene.com